Abstract
Objective
The aim of this study was to compare plasma Platelet-activating factor (PAF) and P-selectin (CD62P) activities in Behçet’s disease patients with and without thrombosis.
Methods
In this cross-sectional and descriptive study, 30 consecutive Behçet’s patients were included, 15 of them with venous thrombosis. All patients were also divided into two subgroups according to the presence or absence of clinical activity. Plasma PAF levels, basal and Ca++ ionophore (A23187)-induced leukocyte (cellular) PAF activities, and platelet-rich plasma ΔCD62P activity (the mean fluorescent density difference between CD62P phycoerythrin-positive and -negative stains) were evaluated.
Results
In the thrombotic group, plasma PAF (P=0.001), basal leukocyte PAF (P=0.017), induced leukocyte PAF (P=0.024), and ΔCD62P (P=0.023) levels were significantly higher than in the nonthrombotic group. In the whole group of Behçet’s patients, there was a positive correlation between plasma PAF and ΔCD62P levels (r=0.533, P=0.002). When we compared clinically active and inactive patients with respect to the above parameters, there was no significant difference, irrespective of thrombosis. Plasma PAF (P=0.001), basal leukocyte PAF (P=0.004), and ΔCD62P (P=0.038) levels were significantly higher in the presence of both clinical activity and thrombosis than of clinical activity alone.
Conclusion
Platelet-activating factor and CD62P may contribute to endothelial injury and thrombosis development in Behçet’s disease. These two parameters seem related to the presence of thrombosis rather than clinical activity.
Similar content being viewed by others
References
Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291
Yazıcı H, Yurdakul S, Hamuryudan V (1999) Behçet’s syndrome. Curr Opin Rheum 11:53–57
Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S et al (1992) Vascular involvement in Behçet’s disease. J Rheumatol 19:402–410
Gül A (2001) Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 19 [Suppl 24]:S6–S12
Braquet P, Shen TY, Touqui L, Vargaftig B (1987) Perspectives in platelet activating factor research. Phamacol Rev 39:97–145
Zimmerman GA, McIntyre TM, Prescott SM (1995) Production of platelet-activating factor by human vascular endothelial cells: evidence of a requirement for specific agonists and modulation by prostacyclin. Circulation 72:718–727
de Bruijne-Admiral LG, Modderman PW, Von dem Borne AEG, Sonnenberg A (1992) P-selectin mediates Ca2+-dependent adhesion of activated platelets to many different types of leukocytes: detection by flow cytometry. Blood 80:134–142
International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
Salari H (1986) Solid-phase extraction and reversed-phase high performance liquid chromatographic technique for isolation and estimation of platelet activating factor in plasma. J Chromatogr 382:89–98
Shattil SJ, Cunningham M, Hoxie JA (1987) Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 70:307–315
Abrams CS, Ellison N, Budzynski AZ, Shattil SJ (1990) Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 75:128–138
Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM (2002) The platelet-activating factor system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 3 [Suppl 5]:S294–S301
Lorant DE, Zimmerman GA, McIntyre TM, Prescott SM (1995) Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Semin Cell Biol 6:295–303
Lehr HA, Weyrich AS, Saetzier RK et al (1997) Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest 99:2358–2364
Elstat MR, La Pinc TR, Cowley FS, McEver RP, McIntyre TM, Prescott SM, Zimmerman GA (1995) P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. J Immunol 155:2109–2122
Tetta C, Bussolino F, Modena V et al (1990) Release of platelet activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 91:244–256
Warren JS, Mandel DM, Johnson KJ, Ward PA (1989) Evidence for the role of platelet activating factor in immune complex vasculitis in the rat. J Clin Invest 83:669–678
Haznedaroğlu Ş, Karaaslan Y, Büyükaşık Y, Koşar A, Özcebe Oİ, Haznedaroğlu IC, Kirazlı Ş, Dündar SV (2000) Selectin adhesion molecules in Behçet’s disease. Ann Rheum Dis 59:61–63
Demopoulos CA, Andrikopoulos NK, Antonopoulou S (1994) A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids 29:305–309
Shinozaki K, Kawasaki T, Kambayashi J, Sakon M, Shiba E, Uemura Y, Ou M, Iwamoto N, Mori T (1994) A new method of purification and sensitive bioassay of platelet-activating-factor (PAF) in human whole blood. Life Sci 54:429–439
Imaizumi T (1991) Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking. Lipids 26:1269–1273
Imaizumi T, Satoh K, Yoshida H, Kawamura Y, Hiramoto M, Koyanagi M, Takamatsu S, Takamatsu M (1990) Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers. Heart Vessels 5:81–86
Miyaura S, Eguchi H, Johnston JM (1992) Effect of a cigarette smoke extract on the metabolism of the proinflammatory autocoid, platelet-activating factor. Circ Res 70:341–347
Sturm MJ, Strophair JM, Kendrew PJ, Vandongen R, Beilin LJ, Taylor RR (1989) Whole blood aggregation and plasma lyso-PAF related to smoking and atherosclerosis. Clin Exp Pharmacol Physiol 16:597–605
Bithell TC (1993) The physiology of primary hemostasis. In: Lee GR, Bithell TC, Foerster J, Atkens JW, Lukens JN (eds) Wintrobe’s clinical hematology, 9th edn. Lea and Febiger, Philadelphia, pp 549–550
Hayashi J, Hiromura K, Koizumi R, Shimizu Y, Maezawa A, Nojima Y, Naruse T (2001) Platelet-activating factor antagonist, SM-12502, attenuates experimental glomerular thrombosis in rats. Nephron 87:274–278
Downing LJ, Wakefield TW, Strieter RM et al (1997) Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg 25:816–827
Myers DD Jr, Henke PK, Wrobleski SK et al (2002) P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J Vasc Surg 36:928–938
Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yakota M (2000) Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150:209–216
Taylor RR, Sturm M, Kendrew PJ, Vandongen R, Beilin LJ (1989) Plasma levels of the lyso-derivative of platelet-activating factor are related to age. Clin Sci (Colch) 76:195–198
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tunc, S.E., Aksu, K., Keser, G. et al. Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet’s patients. Rheumatol Int 25, 326–331 (2005). https://doi.org/10.1007/s00296-004-0450-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-004-0450-4